Enhancing Existing Approaches to Peripheral T-Cell Lymphoma

Seminars in Hematology

Volumn 47, Issue SUPPL. 1, 2010, Pages S8-

  Foss, Francine M ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE; ASPARAGINASE; BLEOMYCIN; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; NAVELBINE; PLATINUM COMPLEX; PREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RETINOIC ACID; VINCRISTINE; VINDESINE;

AGGRESSIVE NK CELL LEUKEMIA; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG MEGADOSE; DRUG RESPONSE; ENTEROPATHY; HEPATOSPLENOMEGALY; HISTOPATHOLOGY; HUMAN; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANNICULITIS; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME;

EID: 77950614635     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.01.012     Document Type: Article

References (18)

1. Abouyabis A.N., Shenoy P.J., Flowers C., Lechowicz M.J. Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis [abstr 3452]. Blood 2007, 110:1011a.
2. Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008, 26:4124-4130.
3. Tilly H., Lepage E., Coiffier B., et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003, 102:4284-4289.
4. Bouabdallah R., Delmer A., Xerri L., Mounier N., Reyes F. ESHAP chemotherapy regimen and 13-cis-retinoic acid in elderly patients with untreated poor-prognosis peripheral T cell lymphoma: a GELA phase II trial of feasibility and efficacy [abstr 322]. Ann Oncol 2005, 16:v131.
5. Arkenau H.T., Chong G., Cunningham D., et al. Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 2007, 92:271-272.
6. Spencer A., Reed K., Arthur C. Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Intern Med J 2007, 37:760-766.
7. Kim J.G., Sohn S.K., Chae Y.S., et al. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 2006, 58:35-39.
8. Delmer A., Fitoussi O., Gaulard P., et al. A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: results of the GELA LNH05-1T trial [abstr 8553]. J Clin Oncol 2009, 27:447s.
9. Gallamini A., Zaja F., Patti C., et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007, 110:2316-2323.
10. Intragumtornchai T., Bunworasate U., Nakorn T.N., Rojnuckarin P. Alemtuzumab in combination with CHOP and ESHAP as first-line treatment in peripheral T-cell lymphoma [abstr 4740]. Blood 2006, 108:268b.
11. Foss F., Sjak-Shie N., Goy A., et al. Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-cell lymphomas (PTCL), the CONCEPT trial [abstr 3449]. Blood 2007, 110:1011a.
12. Dang N.H., Pro B., Hagemeister F.B., et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007, 136:439-447.
13. Lee K.W., Yun T., Kim D.W., et al. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma 2006, 47:1274-1282.
14. Huang H., Lin Z., Lin X., Cai Q., Xia Z., Jiang W. Long-term outcomes of patients with newly diagnosed NK/T-cell lymphoma treated by EPOCH regimen [abstr 2689]. Blood 2009, 114:1052.
15. Jaccard A., Gachard N., Coppo P., et al. A prospective phase II trial of an L-asparaginase containing regimen in patients with refractory or relapsing extra nodal NK/T-cell lymphoma [abstr 579]. Blood 2008, 112:217.
16. Yamaguchi M., Suzuki R., Kwong Y.L., et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008, 99:1016-1020.
17. Reimer P., Ruediger T., Schertlin T., et al. Autologous stem cell transplanation as first line therapy in peripheral T cell lymphomas. Update of a prospective multicenter study [abstr 904]. Blood 2004, 104:258a.
18. Sieniawski M., Lennard J., Millar C., et al. Aggressive primary chemotherapy plus autologous stem cell transplantation improves outcome for peripheral T cell lymphomas compared with CHOP-like regimens [abstr 1660]. Blood 2009, 114:662.